The University of Virginia is participating a clinical research study for adults ages 18 and over, who have mesothelioma. The purpose of the study is to compare the effects of chemotherapy combined with durvalumab, a type of immunotherapy, or to a treatment chosen by your study doctor, which is either chemotherapy or immunotherapy combination (ipilimumab and nivolumab) in mesothelioma.
This is a randomized study. One group is the experimental group (chemotherapy with durvalumab). The other group is the control group (either chemotherapy or immunotherapy with ipilimumab and nivolumab). Before you are randomized your study doctor will choose if you will receive standard chemotherapy or immunotherapy with ipilimumab and nivolumab if you are randomized to the control group. The results of each group are compared to see if one improves survival.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04334759